The Latest Breaking News from Biogen

Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

The whistleblower provision has been around for a long time but it still has plenty of bite.